CDKN1A and neoplasm: A lipid conjugation of MET increased the tumor-suppression activity of the peptide against human pancreatic adenocarcinomas [250], and the MET/opioid growth factor receptor system increased the cyclin-dependent kinase inhibitor p21 protein expression to attenuate the progression of human pancreatic cancer [251].